Dr. Kang on Aprepitant for Preventing CINV in Children

Hyoung Jin Kang, MD, PhD

Hyoung Jin Kang, MD, PhD, associate professor, Department of Pediatrics, Seoul National University, South Korea, discusses a phase III trial of aprepitant for chemotherapy-induced nausea and vomiting (CINV) in children.

Hyoung Jin Kang, MD, PhD, associate professor, Department of Pediatrics, Seoul National University, South Korea, discusses a phase III trial of aprepitant for chemotherapy-induced nausea and vomiting (CINV) in children. This study was presented at the 2014 MASCC/ISOO International Symposium.

Patients aged 12-17 undergoing emetogenic chemotherapy were randomized to receive aprepitant capsule 125 mg and ondansetron before chemotherapy (on day 1) and aprepitant capsule 80 mg (on days 2-3) or placebo (on days 1-3) plus ondansetron (on day 1). A total of 302 patients were evaluated.

Researchers concluded that the drug combination with aprepitant was well tolerated and more effective in preventing CINV. Kang says these data can be practice-changing for supportive care for pediatric patients.